182 related articles for article (PubMed ID: 36662602)
21. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
Olson NE; Ragan SP; Reiss DJ; Thorpe J; Kim Y; Abramson JS; McCoy C; Newhall KJ; Fox BA
Mol Cancer Ther; 2023 Mar; 22(3):406-418. PubMed ID: 36595660
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
23. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
24. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.
Ryan CE; Jacobson CA
Semin Hematol; 2023 Nov; 60(5):322-328. PubMed ID: 38199906
[TBL] [Abstract][Full Text] [Related]
25. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
Choe JH; Yu T; Abramson JS; Abou-El-Enein M
Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
[TBL] [Abstract][Full Text] [Related]
27. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Elmacken M; Peredo-Pinto H; Wang C; Xu Z; Tegenge M; Jaigirdar AA; Theoret MR; Purohit-Sheth T; Kasamon YL
Clin Cancer Res; 2024 Feb; ():. PubMed ID: 38324398
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
[TBL] [Abstract][Full Text] [Related]
30. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
31. Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Future Oncol; 2024 Mar; ():. PubMed ID: 38547003
[TBL] [Abstract][Full Text] [Related]
32. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract][Full Text] [Related]
33. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J
Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418
[TBL] [Abstract][Full Text] [Related]
34. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
Duarte C; Kamdar M
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G; Paruzzo L; Patel V; Svoboda J; Chong ER; Fardella E; Chong EA; Gabrielli G; Nasta SD; Landsburg DJ; Carter J; Pajarillo R; Barta SK; White G; Weber E; Napier E; Porter DL; Garfall AL; Schuster SJ; Ruella M
J Hematol Oncol; 2024 Apr; 17(1):19. PubMed ID: 38644469
[TBL] [Abstract][Full Text] [Related]
38. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
39. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Abramson JS; Palomba ML; Gordon LI; Lunning M; Wang M; Arnason J; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Dehner C; Kim Y; Ogasawara K; Kostic A; Siddiqi T
Blood; 2024 Feb; 143(5):404-416. PubMed ID: 37890149
[TBL] [Abstract][Full Text] [Related]
40. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
Cartron G; Fox CP; Liu FF; Kostic A; Hasskarl J; Li D; Bonner A; Zhang Y; Maloney DG; Kuruvilla J
Exp Hematol Oncol; 2022 Mar; 11(1):17. PubMed ID: 35337365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
